First Quarter 2025 Earnings May 12, 2025 " Legal Information IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix (the "Merger"), Quanterix will file with the U.S. Securities and Exchange Commission (the "SEC") a post-effective amendment to its registration statement on Form S-4 (as so amended, the "Registration Statement"), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the "Proxy ...

Financial Data and Key Metrics Changes - Quanterix reported revenue of $35.2 million for Q4 2024, an 11% increase year-over-year [10][28] - Non-GAAP gross margin improved to 57.7%, up 300 basis points from the previous year [11][31] - Cash usage declined by 31% to $4.4 million in Q4 2024 [11] Business Line Data and Key Metrics Changes - Accelerator lab revenue reached $8.6 million, a 22% increase driven by clinical trial testing services [29] - Consumable revenue remained flat at $17.4 million as customers transitioned to Advantage PLUS assays [29] - Instrument revenue decreased by 7% to $3.1 million but increased by 29% sequentially [30] Market Data and Key Metrics Changes - North America led revenue growth with a 17% increase, while Europe grew by 11% and Asia-Pacific declined by 6% for the full year [35] - The customer mix for the year was approximately 54% pharma and 46% academia [34] Company Strategy and Development Direction - The company aims to grow its leadership in neurology and expand into immunology and oncology markets through the Simoa ONE platform and the acquisition of Akoya Biosciences [15][20] - Quanterix plans to build a global diagnostic testing infrastructure for Alzheimer's disease, having added 12 partners to its network [17][18] - The company expects to achieve $40 million in operating synergies from the Akoya acquisition by 2026 [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Accelerator business despite market volatility, citing a strong pipeline and diverse customer base [26][52] - The company anticipates a revenue range of $140 million to $146 million for 2025, reflecting a growth of 2% to 6% [40] - Management noted that 20% to 25% of annual revenues are tied to U.S. academic customers, which are expected to decline by 10% in 2025 [41] Other Important Information - The company ended Q4 2024 with $291.7 million in cash and equivalents [36] - Adjusted EBITDA was negative $23.6 million in 2024, compared to negative $19 million in 2023 [38] Q&A Session Summary Question: Impact of NIH academic government on revenue - Management acknowledged the pressure from NIH and indicated that the academic market is experiencing paralysis, affecting decision-making and spending [58][76] Question: Confidence in second half recovery - Management expressed confidence in the Accelerator business, citing a strong pipeline and expected larger projects to materialize in the second half of the year [52][75] Question: Details on validation phase with hospitals - Management confirmed that 10 hospitals are in the validation phase, with some actively in contract negotiations [54] Question: Concerns about the Akoya merger - Management emphasized the long-term value of the Akoya merger, focusing on recurring revenues and synergies [60][82] Question: Revenue guidance and academic market assumptions - Management indicated that the guidance incorporates expected declines in the academic market and potential upside if funding improves [77][88] Question: Simoa ONE launch impact - Management expects the Simoa ONE platform to launch at the end of 2025, expanding the addressable market in immunology and oncology [67][70] Question: Growth expectations outside the U.S. - Management anticipates low double-digit to high single-digit growth outside the U.S., aligned with overall expectations for 2024 [103]

March 17, 2025 Legal Information IMPORTANT ADDITIONAL INFORMATION " Fourth Quarter & Full Year 2024 Earnings In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix (the "Merger"), Quanterix filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4, dated February 13, 2025 (the "Registration Statement"), which contains a preliminary joint proxy statement of Quanterix and Akoya and a preliminary prospectus of Quanterix (the " ...